Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization

In up to 30% of non-small cell lung cancer (NSCLC) patients, the oncogenic driver of tumor growth is a constitutively activated epidermal growth factor receptor (EGFR). Although these patients gain great benefit from treatment with EGFR tyrosine kinase inhibitors, the development of resistance is in...

Descripción completa

Detalles Bibliográficos
Autores principales: Schueler, Julia, Tschuch, Cordula, Klingner, Kerstin, Bug, Daniel, Peille, Anne-Lise, de Koning, Leanne, Oswald, Eva, Klett, Hagen, Sommergruber, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678194/
https://www.ncbi.nlm.nih.gov/pubmed/31323891
http://dx.doi.org/10.3390/cells8070740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678194/
https://www.ncbi.nlm.nih.gov/pubmed/31323891
http://dx.doi.org/10.3390/cells8070740

Ejemplares similares